U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

https://www.merckvaccines.com/capvaxive/wp-content/uploads/sites/153/2024/06/Merck-News-Release-06-17-24-CAPVAXIVE-FDA-Approval.pdf